Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Egyptian Rheumatology and Rehabilitation

Table 5 Comparison between different types of biologics in PsA as regards WBCs, RBCs, and platelets indices

PSA	Biologics									ANOVA
	Golimumab			Secukinumab			Adalimumab-atto			ANOVA
	Mean	±	SD	Mean	±	SD	Mean	±	SD	F	P value
WBCS	5.725	±	2.149	7.678	±	2.158	6.390	±	1.667	3.507	0.040*
Neutrophils	3.533	±	1.719	4.922	±	1.534	4.160	±	1.212	3.067	0.059
Lymphocyte	1.875	±	0.658	2.219	±	0.648	2.000	±	0.514	1.171	0.321
HCT	36.717	±	1.067	37.433	±	1.120	37.910	±	1.869	2.286	0.116
RBCs	4.703	±	0.474	4.739	±	0.396	4.794	±	0.545	0.109	0.897
Hb	12.375	±	0.609	12.739	±	1.309	13.060	±	1.295	0.991	0.381
MCV	79.233	±	5.262	80.700	±	4.902	81.410	±	4.501	0.581	0.565
MCH	22.425	±	4.020	25.511	±	3.826	26.070	±	2.623	3.510	0.040*
RDW%	12.333	±	1.233	13.772	±	1.923	13.060	±	1.616	2.699	0.080
PLT	269.917	±	83.981	232.056	±	54.072	214.900	±	65.910	2.018	0.147
MPV/fl	8.450	±	0.639	9.139	±	1.176	8.250	±	1.023	3.083	0.058
PDW	11.483	±	1.503	12.839	±	3.397	12.130	±	2.213	0.938	0.401
Hb/PLT ratio	0.049	±	0.013	0.058	±	0.015	0.066	±	0.023	2.795	0.074
RDW%/PLT ratio	0.048	±	0.013	0.062	±	0.016	0.069	±	0.024	4.191	0.023*
RBCs/PLT ratio	0.020	±	0.007	0.021	±	0.005	0.023	±	0.008	0.579	0.565
Hb/RDW% ratio	1.012	±	0.107	0.939	±	0.148	1.011	±	0.144	1.375	0.266
Neutrophil/lymphocyte ratio	1.877	±	0.560	2.254	±	0.399	2.118	±	0.500	2.266	0.118
PLT/lymphocyte ratio	153.553	±	47.659	113.377	±	43.496	111.184	±	34.773	3.841	0.031*

PsA psoriatic arthritis, DD disease duration, WBCs white blood cells, HCT hematocrit, RBCs red blood cells, HB hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, RDW red cell distribution width, PLT platelet, MPV mean platelet volume, PDW platelet distribution width, SD standard deviation. Level of significance: P ≤ 0.05: significant, P < 0.005: highly significant